What are the main indications for veentuzumab/besifu

The main indications of Enfortumab/Enfortumab are focused on the treatment of locally advanced or metastatic urothelial carcinoma (mUC; bladder cancer). Its clinical use can be divided into two options: combination therapy and monotherapy. In terms of combination therapy, Enfortumab can be used in combination with the immune checkpoint inhibitor pembrolizumab to treat eligible adult patients. It can enhance the anti-tumor effect through synergy and improve patient response rates and survival benefits.

As monotherapy,Enfortumab is indicated for patients with locally advanced or metastatic urothelial cancer who have typically previously received programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitors and platinum-containing chemotherapy regimens; or who are ineligible for cisplatin-containing chemotherapy due to health or tolerability and have received one or more prior therapies. Through this strict indication definition, Enfortumab can provide effective follow-up treatment options for patients for whom standard treatment options have failed or are not feasible.

Enfortumab has a unique targeting mechanism, which induces cell death by recognizing surface antigens of urothelial cancer cells while reducing its toxic effects on normal cells, allowing it to demonstrate good efficacy and tolerability in the treatment of advanced cancer. This precise targeting not only provides new treatment hope for patients, but also provides an important reference for doctors when formulating individualized treatment plans.

In summary, veentuzumab/Bisifu has clear clinical value in the field of urothelial cancer. Its indications cover two types of patients: combination immunotherapy and monotherapy, providing an effective clinical treatment option for locally advanced and metastatic urothelial cancer. With the continuous expansion of clinical applications and the gradual improvement of policies, it is expected that its medical insurance reimbursement and accessibility will further improve in the future, providing patients with more treatment protection.

Reference: https://www.padcev.com/